Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Earnings Results, Beats Estimates By $0.06 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA) released its earnings results on Thursday. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06, Zacks reports. The company had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.02% and a negative net margin of 8.59%. Vanda Pharmaceuticals updated its FY 2030 guidance to EPS and its FY 2025 guidance to EPS.

Vanda Pharmaceuticals Stock Down 6.0 %

Shares of Vanda Pharmaceuticals stock traded down $0.28 on Friday, reaching $4.42. The company’s stock had a trading volume of 1,978,333 shares, compared to its average volume of 559,972. The company has a market capitalization of $257.73 million, a price-to-earnings ratio of -15.79 and a beta of 0.74. The firm’s fifty day simple moving average is $4.62 and its two-hundred day simple moving average is $4.87. Vanda Pharmaceuticals has a 52 week low of $3.71 and a 52 week high of $6.75.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on VNDA. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, February 4th. StockNews.com began coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a “hold” rating for the company.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.